Moreover, acitretin (RAR agonist) entered Phase II clinical trials in Germany in 2010, and the preliminary results reported 25% increase in AβPPs-α in CSF of mild to moderate AD patients in the treatment group [29]. This evidence concerns the gene RARA and Alzheimer disease.